ReviewThe journal of headache and pain2019
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Review in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 6 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis.The journal of headache and pain · 2025Pooled it
- Assessing the occurrence of hypertension in patients receiving calcitonin gene-related peptide monoclonal antibodies for episodic and chronic migraine: a systematic review and meta-analysis.Journal of oral & facial pain and headache · 2024Pooled it
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.The journal of headache and pain · 2022Guideline
- Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Comorbidities of primary headache disorders: a literature review with meta-analysis.The journal of headache and pain · 2021Pooled it
- Pooled it
- Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.Endocrinology, diabetes & metabolism · 2021Trial
- Trial
- αCGRP Activates PI3K/Akt to Exert Antioxidant Effects and Improve the Survival Rate and Functional Status of Cortical Neurons.Molecular neurobiology · 2026Article
- Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure.Cardiovascular drugs and therapy · 2026Review
- Trigeminovascular calcitonin gene-related peptide release and peripheral vascular responses in a mouse model of accelerated aging: Implications for migraine.The journal of headache and pain · 2026Article
- Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study.Journal of ultrasonography · 2026Article
- Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant-Treated Migraine Cohort.Journal of clinical medicine · 2026Article
- Sex-dependent modulation of CGRPergic neurovascular activity by 5-CT in rats.Frontiers in pharmacology · 2026Article
- Potential Drug Targets for Migraine Identified Through Mendelian Randomization Analysis of the Human Plasma Proteome.Molecular neurobiology · 2025Article
- Electroacupuncture of Guanyuan (CV4) Acupoint Improved Pelvic Inflammatory Disease Pain by Inhibiting Neuroinflammation and Sympathetic Activity.Immunity, inflammation and disease · 2025Article
- The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group.European journal of neurology · 2025Review
- CGRP-related neuropeptide adrenomedullin 2 promotes tissue-protective ILC2 responses and limits intestinal inflammation.Nature immunology · 2025Article
- Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system.The journal of headache and pain · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs.In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.